DHX9 Inhibitor Compounds Enhancing Selectivity and Efficacy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for DHX9 inhibitors as potential therapeutic agents for treating diseases or disorders that are responsive to DHX9 inhibition, given its regulatory roles in cancer and other diseases involving gene replication, translation, or regulation.
Innovation Solution
The development of compounds with Formula I, or their pharmaceutically acceptable salts, which act as DHX9 inhibitors. These compounds are designed to modulate DHX9 activity, potentially offering therapeutic benefits in treating diseases associated with DHX9 regulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If DHX9 inhibition is achieved through small molecule compounds, then therapeutic efficacy in cancer treatment is improved, but compound specificity and selectivity become critical challenges
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features at particular positions to enhance DHX9 selectivity. The core structure with specific substituents at defined positions (Formula I) creates localized interactions with DHX9 that distinguish it from other helicases, thereby improving compound specificity while maintaining therapeutic efficacy.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters such as substituent types, positions, and stereochemistry in the Formula I compounds. This allows optimization of the balance between DHX9 binding affinity (for efficacy) and selectivity against other targets, resolving the contradiction through precise molecular parameter control.
2Adaptability or versatility
If DHX9 inhibitors are developed for broad disease treatment, then therapeutic versatility is improved, but understanding of mechanism of action and selectivity becomes more complex
Solution Approach 1:
The patent applies universality by developing Formula I compounds that can treat multiple DHX9-driven diseases (cancers, viral infections, autoimmune disorders) through a common mechanism of DHX9 inhibition. This multi-functional approach achieves therapeutic versatility while the core molecular structure remains consistent, managing complexity through a universal inhibitor platform.
Solution Approach 2:
The patent uses DHX9 as an intermediary target that mediates multiple disease pathways. By inhibiting this single helicase enzyme, the compounds indirectly affect multiple disease processes (gene replication, translation, regulation), achieving broad therapeutic versatility while simplifying the mechanism understanding to focus on DHX9 as the central mediator.
Data Source
AI summary
Provided are compounds of the Formula (I):or pharmaceutically acceptable salts thereof, which are useful for the inhibition of DHX9 and in the treatment of a variety of DHX9 mediated conditions or diseases, such as cancer.